Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$34.78 USD
-2.77 (-7.38%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $34.75 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$34.78 USD
-2.77 (-7.38%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $34.75 -0.03 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Why Is Celldex (CLDX) Down 29.2% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
by Zacks Equity Research
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLDX) Outperforming Other Medical Stocks This Year?
Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss, while sales miss estimates in the fourth quarter of 2018.
Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Celldex Therapeutics (CLDX) closed at $5.92, marking a -1.17% move from the previous day.
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Why Is Celldex (CLDX) Down 29% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q3. Revenues fall on reduced contract revenues and also miss estimates.
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 46.67% and -54.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Celldex Therapeutics (CLDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Celldex (CLDX) Up 3.3% Since Last Earnings Report?
by Zacks Equity Research
Celldex (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Celldex (CLDX) delivered earnings and revenue surprises of 21.43% and 2.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.
Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Celldex Therapeutics (CLDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
by Zacks Equity Research
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down
by Indrajit Bandyopadhyay
Celldex (CLDX) beat earnings and sales estimates in the first quarter.
What's in Store for Celldex (CLDX) This Earnings Season?
by Zacks Equity Research
With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is on its immuno-oncology pipeline.
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
by Zacks Equity Research
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options
by Zacks Equity Research
Surging implied volatility makes Celldex Therapeutics (CLDX) stock lucrative to the option traders.